Loading institutional data...
Loading institutional data...
Held by 332 of 5,944 reporting institutions (95th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Solve the discounted cash flow backwards, then stress-test the assumptions.
This company doesn't have positive free cash flow, so a reverse DCF can't be run.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
3/8 of the 9 checks — 1 couldn't be scored (see above), so the score is out of the 8 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Needs granular two-year detail (receivables, PP&E, D&A, SG&A) — not fully reported.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Coverage data unavailable; leverage falling year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $25M buybacks = $25M returned on -$307M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: -36%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $801M covers the $0 due within a year 801282000.0× over. Scheduled principal only (excludes interest & revolver draws). As of 2025-09-30 (10-Q).
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest. Effective rate ~4.6% on $829M of debt.
Cash vs short-term debt unavailable.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-09-18
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.20B 100.0% | $1.90B 100.0% | $1.24B 100.0% | $933.0M 100.0% | $701.9M 100.0% | $540.1M 100.0% | $380.8M 100.0% | $301.0M 100.0% | $154.6M 100.0% | $5.4M 100.0% |
| Cost of Revenue | $25.5M 1.2% | — | — | — | — | — | — | — | — | $130K 2.4% |
| Cost of Products | — | — | — | — | — | — | — | — | — | $130K 2.4% |
| Research & Development | — | — | — | — | — | — | — | $401.8M 133.5% | $166.7M 107.8% | $188.3M 3473.0% |
| Selling, General & Admin | $491.7M 22.4% | $557.9M 29.3% | $481.9M 38.8% | $451.4M 48.4% | $282.7M 40.3% | $317.9M 58.9% | $284.8M 74.8% | $207.8M 69.0% | $122.7M 79.4% | $83.7M 1544.9% |
| Total Operating Expenses | $2.90B 131.8% | $1.68B 88.5% | $1.51B 121.5% | $1.47B 157.5% | $1.16B 165.5% | $1.10B 204.5% | $1.09B 285.3% | $644.7M 214.1% | $326.2M 211.0% | $272.2M 5020.3% |
| Operating Income | -$699.8M -31.8% | $218.1M 11.5% | -$267.8M -21.5% | -$536.2M -57.5% | -$459.7M -65.5% | -$564.2M -104.5% | -$705.6M -185.3% | -$343.6M -114.1% | -$171.6M -111.0% | -$266.7M -4920.3% |
| Interest Expense | -$38.1M -1.7% | -$18.4M -1.0% | -$22.0M -1.8% | -$53.2M -5.7% | $63.5M 9.1% | $59.9M 11.1% | $30.7M 8.1% | $33.7M 11.2% | $5.8M 3.8% | $1.9M 34.9% |
| Interest & Investment Income | $30.8M 1.4% | $30.6M 1.6% | $36.3M 2.9% | $16.5M 1.8% | $354K 0.1% | $3.0M 0.5% | $7.2M 1.9% | $6.8M 2.3% | $1.8M 1.2% | $507K 9.4% |
| Other Income (Expense), net | -$2.4M -0.1% | $42.7M 2.2% | -$252.3M -20.3% | -$153.8M -16.5% | $40.8M 5.8% | $11.1M 2.1% | -$8.3M -2.2% | -$19.0M -6.3% | $123.0M 79.6% | -$535K -9.9% |
| Pretax Income | -$702.2M -31.9% | $260.8M 13.7% | -$520.1M -41.8% | -$690.0M -73.9% | -$418.9M -59.7% | -$553.1M -102.4% | -$713.9M -187.5% | -$362.6M -120.5% | -$48.6M -31.5% | -$267.3M -4930.2% |
| Income Tax Expense | $11.2M 0.5% | $25.5M 1.3% | $15.9M 1.3% | $13.5M 1.4% | -$168K -0.0% | $1.1M 0.2% | $1.2M 0.3% | -$692K -0.2% | $2.1M 1.3% | — |
| Net Income | -$713.4M -32.5% | $235.2M 12.4% | -$536.0M -43.1% | -$703.5M -75.4% | -$418.8M -59.7% | -$554.1M -102.6% | -$715.1M -187.8% | -$361.9M -120.2% | -$50.7M -32.8% | -$267.3M -4930.2% |
| Per Share | ||||||||||
| EPS (Basic) | $-7.13 | $2.47 | $-5.80 | $-8.03 | $-5.15 | $-7.11 | — | — | — | — |
| EPS (Diluted) | $-7.13 | $2.34 | $-5.80 | $-8.03 | $-5.15 | $-7.11 | — | — | — | — |
| Weighted Avg Shares (Basic) | 100.1M | 95.1M | 92.4M | 87.6M | 81.3M | 78.0M | 73.6M | 66.3M | 58.8M | 48.7M |
| Weighted Avg Shares (Diluted) | 100.1M | 107.9M | 92.4M | 87.6M | 81.3M | 78.0M | 73.6M | 66.3M | 58.8M | — |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
EOD close · as of 2026-09-18
Where each multiple sits in its own 14-yr range · 0th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | — | — | — | — | — | — | — | 1.2 |
| R&D | 133.5 | — | — | — | — | — | — | — |
| SG&A | 69.0 | 74.8 | 58.9 | 40.3 | 48.4 | 38.8 | 29.3 | 22.4 |
| Operating Income | -114.1 | -185.3 | -104.5 | -65.5 | -57.5 | -21.5 | 11.5 | -31.8 |
| Income Tax | -0.2 | 0.3 | 0.2 | -0.0 | 1.4 | 1.3 | 1.3 | 0.5 |
| Net Income | -120.2 | -187.8 | -102.6 | -59.7 | -75.4 | -43.1 | 12.4 | -32.5 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on SRPT: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| SRPT | $2.2B | — | — | 1.0× | 15.6% | 98.8% | -32.5% | -62.5% | -36.2% | -1.3× | 332 |
Peers = companies sharing SRPT's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.